Sphingolipid and endocannabinoid profiles in adult attention deficit hyperactivity disorder

Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concen
Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool.
…show moreshow less

Metadaten
Author:Nathalie Brunkhorst-Kanaan, Sandra Trautmann, Yannick Schreiber, Dominique Thomas, Sarah Kittel-Schneider, Robert Gurke, Gerd Geisslinger, Andreas Reif, Irmgard Tegeder
URN:urn:nbn:de:hebis:30:3-634487
DOI:http://dx.doi.org/10.3390/biomedicines9091173
ISSN:2227-9059
Parent Title (English):Biomedicines
Publisher:MDPI
Place of publication:Basel
Document Type:Article
Language:English
Date of Publication (online):2021/09/06
Date of first Publication:2021/09/06
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/11/26
Tag:attention deficit hyperactivity disorder; bipolar disorder; ceramides; endocannabinoids; major depression; tandem mass spectrometry
Volume:9
Issue:9, art. 1173
Pagenumber:15
First Page:1
Last Page:15
Note:
The study was supported by the Deutsche Forschungsgemeinschaft, DFG (CRC1039, A03 to IT and CRC1039, Z01 to GG; CRC1080 C02 to I.T.) and by the Fraunhofer Cluster of Excellence for immune mediated diseases (CIMD, to GG). The funders had no role in the collection, analyses, and interpretation of data, writing of the manuscript, or the decision to submit the article for publication.
HeBIS PPN:488812097
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Open-Access-Publikationsfonds:Medizin
Licence (German):License LogoCreative Commons - Namensnennung 4.0

$Rev: 11761 $